PRMT5 and glioblastoma: Preclinical studies, in vitro and in vivo, revealed that among the PRMT5 inhibitors, treatment of glioblastoma with compound 5 (CMP5) reflects the impact of PRMT5 knockdown, which results in apoptosis of differentiated cells driven into a nonreplicated aging state [27].